<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512451943</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512451943</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Radiologically isolated syndrome – incidental magnetic resonance imaging findings suggestive of multiple sclerosis, a systematic review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Granberg</surname><given-names>Tobias</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451943">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Martola</surname><given-names>Juha</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451943">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kristoffersen-Wiberg</surname><given-names>Maria</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451943">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Aspelin</surname><given-names>Peter</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512451943">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fredrikson</surname><given-names>Sten</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512451943">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512451943"><label>1</label>Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Sweden</aff>
<aff id="aff2-1352458512451943"><label>2</label>Department of Clinical Neuroscience, Karolinska Institutet, Sweden</aff>
<author-notes>
<corresp id="corresp1-1352458512451943">Tobias Granberg, Department of Clinical Science, Intervention and Technology, C1-46, Karolinska University Hospital, SE-141 86 Stockholm, Sweden. Email: <email>tobias.granberg@ki.se</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>271</fpage>
<lpage>280</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>3</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>With increasing availability of magnetic resonance imaging (MRI), there is also an increase in incidental abnormal findings. MRI findings suggestive of multiple sclerosis in persons without typical multiple sclerosis symptoms and with normal neurological findings are defined as radiologically isolated syndrome (RIS). Half of the persons with RIS have their initial MRI because of headache, and some have a subclinical cognitive impairment similar to that seen in multiple sclerosis. Radiological measurements also show a similarity between RIS and multiple sclerosis. Approximately two-thirds of persons with RIS show radiological progression and one-third develop neurological symptoms during mean follow-up times of up to five years. Cervical cord lesions are important predictors of clinical conversion. Management has to be individualised, but initiation of disease modifying therapy is controversial and not recommended outside of clinical trials since its effects have not been studied in RIS. Future studies should try to establish the prevalence and long-term prognosis of RIS, its impact on quality of life, and define the role of disease modifying therapy in RIS.</p>
</abstract>
<kwd-group>
<kwd>Radiologically isolated syndrome</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>magnetic resonance imaging</kwd>
<kwd>incidental findings</kwd>
<kwd>unexpected</kwd>
<kwd>RIS</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458512451943" sec-type="intro">
<title>Introduction</title>
<p>MRI has become increasingly available since its clinical introduction in the early 1980s. Over 200 million MRI examinations had been performed by 2006, and the number of examinations continues to increase rapidly<sup><xref ref-type="bibr" rid="bibr1-1352458512451943">1</xref></sup> – see <xref ref-type="fig" rid="fig1-1352458512451943">Figure 1</xref>.<sup><xref ref-type="bibr" rid="bibr2-1352458512451943">2</xref></sup> With increasing availability, there has also been an increase in abnormal incidental findings,<sup><xref ref-type="bibr" rid="bibr3-1352458512451943">3</xref></sup> and an increased awareness of MRI findings suggestive of multiple sclerosis (MS) in patients without typical MS symptoms.<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup> In 2009, Okuda and colleagues defined this entity as radiologically isolated syndrome (RIS).<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup> Since then, studies have been published describing the prognosis of small RIS cohorts, showing that persons with RIS are at high risk of developing MS.<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref><xref ref-type="bibr" rid="bibr5-1352458512451943"/><xref ref-type="bibr" rid="bibr6-1352458512451943"/><xref ref-type="bibr" rid="bibr7-1352458512451943"/><xref ref-type="bibr" rid="bibr8-1352458512451943"/><xref ref-type="bibr" rid="bibr9-1352458512451943"/><xref ref-type="bibr" rid="bibr10-1352458512451943"/><xref ref-type="bibr" rid="bibr11-1352458512451943"/>-<xref ref-type="bibr" rid="bibr12-1352458512451943">12</xref></sup> The role and importance of RIS have been discussed at the latest revision of the McDonald criteria.<sup><xref ref-type="bibr" rid="bibr13-1352458512451943">13</xref></sup> However, RIS is a new and complex entity and there are some fundamental issues that need answering in order to clarify its association to MS. The aim of this systematic review is to describe the current literature on RIS and shed light on the fundamental questions associated with it.</p>
<fig id="fig1-1352458512451943" position="float">
<label>Figure 1.</label>
<caption>
<p>Trends in MRI usage. Example of three high-income countries that have provided statistics of annual number of MRI examinations performed per 1000 population.<sup><xref ref-type="bibr" rid="bibr2-1352458512451943">2</xref></sup></p>
</caption>
<graphic xlink:href="10.1177_1352458512451943-fig1.tif"/></fig>
</sec>
<sec id="section2-1352458512451943">
<title>Search strategy and selection criteria</title>
<p>A systematic literature search was performed in PubMed, embase, Scopus, and Web of Knowledge with search strings containing ‘Radiologically Isolated Syndrome’, ‘Radiologically uncovered Asymptomatic Possible Inflammatory-Demyelinating Disease’ and ‘RIS’, ‘RAPIDD’, ‘accidental’, ‘asymptomatic’, ‘clinically silent’, ‘incidental’, ‘subclinical’, ‘unanticipated’, ‘unexpected’, ‘unsuspected’ in combination with ‘multiple sclerosis’. If more than 100 results were retrieved in the PubMed search, ‘AND MRI’ was added to the search string. MeSH terms were used for MS and MRI. No filters, language restrictions or publication date restrictions were used. Abstracts were screened independently by two raters (TG and JM) and any discrepancies were decided by a third rater (MK-W). Articles considered to have information regarding the prevalence and/or the prognosis of RIS were included. A complete description of the search methodology is presented in the supplementary appendix in the online version of this article.</p>
</sec>
<sec id="section3-1352458512451943">
<title>Terminology and definition</title>
<p>Several different names have been used to define MRI findings suggestive of MS in patients without typical MS symptoms, with a normal neurological examination and no better explanation of the findings. In 2009, two suggestions of nomenclature were proposed. Okuda and colleagues suggested radiologically isolated syndrome, while Siva and colleagues suggested the term radiologically uncovered asymptomatic possible inflammatory-demyelinating disease (RAPIDD).<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref>,<xref ref-type="bibr" rid="bibr8-1352458512451943">8</xref></sup></p>
<p>Siva and colleagues refer to the definition of a syndrome as ‘a combined set of symptoms that occur together frequently enough to suggest a distinct clinical picture’ and state that they prefer RAPIDD, in the context that these findings by definition are asymptomatic.<sup><xref ref-type="bibr" rid="bibr8-1352458512451943">8</xref></sup> On the other hand, RAPIDD might be even less suitable since it suggests that the entity is a ‘disease’, while the patients are neurologically symptomless and might remain unaffected.</p>
<p>In a radiological setting, the abbreviation RIS is unfortunate since it has a widespread use as the abbreviation for the software for digital storage of radiological examinations and data, called radiology information system.14 On the other hand, some persons with MRI findings suggestive of MS later on progress clinically, why radiologically isolated syndrome has the advantage of its resemblance to clinically isolated syndrome (CIS).<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup> Radiologically isolated syndrome, however, seems to have become the convention and has recently been adapted in a textbook.<sup><xref ref-type="bibr" rid="bibr15-1352458512451943">15</xref></sup> RIS is therefore used throughout this review. The definition of RIS according to Okuda and colleagues is presented in <xref ref-type="table" rid="table1-1352458512451943">Table 1</xref>.<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup> An example of such a case is presented in <xref ref-type="fig" rid="fig2-1352458512451943">Figure 2</xref>.</p>
<table-wrap id="table1-1352458512451943" position="float">
<label>Table 1.</label>
<caption>
<p>Definition of RIS according to Okuda and colleagues.<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-1352458512451943" xlink:href="10.1177_1352458512451943-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>A</td>
<td>The presence of incidentally identified CNS white matter anomalies meeting the following MRI criteria:</td>
</tr>
<tr>
<td/>
<td> 1. Ovoid, well-circumscribed, and homogeneous foci with or without involvement of the corpus callosum</td>
</tr>
<tr>
<td/>
<td> 2. T2 hyperintensities measuring &gt;3mm and fulfilling Barkhof criteria (at least three out of four) for dissemination in space</td>
</tr>
<tr>
<td/>
<td> 3. CNS white matter anomalies not consistent with a vascular pattern</td>
</tr>
<tr>
<td>B</td>
<td>No historical accounts of remitting clinical symptoms consistent with neurologic dysfunction</td>
</tr>
<tr>
<td>C</td>
<td>The MRI anomalies do not account for clinically apparent impairments in social, occupational or generalized areas of functioning</td>
</tr>
<tr>
<td>D</td>
<td>The MRI anomalies are not due to the direct physiologic effects of substances (recreational drug abuse, toxic exposure) or a medical condition</td>
</tr>
<tr>
<td>E</td>
<td>Exclusion of individuals with MRI phenotypes suggestive of leukoaraiosis or extensive white matter pathology lacking involvement of the corpus callosum</td>
</tr>
<tr>
<td>F</td>
<td>The CNS MRI anomalies are not better accounted for by another disease process</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512451943">
<p>CNS: central nervous system</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig2-1352458512451943" position="float">
<label>Figure 2.</label>
<caption>
<p>Coronal and sagittal fluid attenuated inversion recovery (FLAIR) images of a 28-year-old male who participated in a MRI study as a healthy volunteer. These initial MRI images were obtained on a 1.5 T machine and demonstrated 15 T2-hyperintense lesions. Most lesions were periventricular, two lesions were juxtacortical. No infratentorial lesions were found. Initial imaging did not include administration of contrast media or spinal imaging. Although the images fulfilled the modified Barkhof criteria, the subject did not have any neurological symptoms and a clinical examination did not reveal any abnormal neurological findings. Radiological and clinical follow-up one year later did not show any change.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451943-fig2.tif"/></fig>
</sec>
<sec id="section4-1352458512451943">
<title>Prevalence</title>
<p>Incidental findings suggestive of MS in patients without symptoms of MS are not newly discovered phenomena, although before the introduction of MRI these were only discovered in post-mortem examinations. This has been shown in four large anatomo-pathological studies published several decades ago. The first was a Swiss study from 1961 of 15,644 autopsies that found 12 cases (0.08%) of unexpected MS findings without a previous history of MS symptoms.<sup><xref ref-type="bibr" rid="bibr16-1352458512451943">16</xref></sup> In 1983, a Canadian study of 2450 autopsies found five cases (0.2%) of unsuspected MS.<sup><xref ref-type="bibr" rid="bibr17-1352458512451943">17</xref></sup> In 1989, a Danish study of 16,100 autopsies found 13 cases (0.08%) of clinically silent MS.<sup><xref ref-type="bibr" rid="bibr18-1352458512451943">18</xref></sup> In 1996, a second Danish study of 7252 autopsies in patients with psychiatric disorders found 23 cases (0.3%) of suspected MS, but none of the demyelinating findings were unexpected or clinically silent.<sup><xref ref-type="bibr" rid="bibr19-1352458512451943">19</xref></sup></p>
<p>There are limitations as to how well these studies reflect the true prevalence of subclinical MS in the community. Since the findings were discovered post-mortem, it is impossible to know whether these patients were truly asymptomatic and if they would have had a normal neurological examination. Secondly, the populations studied were not representative of the community since there was a selection bias as to who was the subject of an autopsy. It is also questionable whether these figures would be accurate today, as the prevalence of MS is increasing and the incidence is increasing regionally.<sup><xref ref-type="bibr" rid="bibr20-1352458512451943">20</xref></sup></p>
<p>Since the introduction of MRI, several studies have described incidental MRI findings suggestive of MS. A study from 1996 conducted in an inpatient psychiatry setting in Boston, Massachusetts, USA, found 23 cases of MRI findings highly suggestive of MS according to Paty’s criteria for MS among 2783 investigated patients.<sup><xref ref-type="bibr" rid="bibr21-1352458512451943">21</xref></sup> This prevalence of 0.8% does, however, not represent RIS since 56.5% of these patients (i.e. 13 patients) had neurological symptoms, without specification. It is also unclear whether they had a neurological examination and whether it revealed any abnormal findings.</p>
<p>The closest estimate to a prevalence study of RIS in a healthy population comes from a German study published in 2006.<sup><xref ref-type="bibr" rid="bibr22-1352458512451943">22</xref></sup> The study showed that among 2536 healthy male recruits, with a mean age of 20.5 years, there was one person with several white matter hyperintensities, some with a circular gadolinium contrast medium enhancement. These findings were classified as ‘demyelinating disease’ and further testing revealed presence of oligoclonal bands in the cerebrospinal fluid, but it was not stated whether the individual had neurological symptoms and whether there were any abnormalities at neurological examination.</p>
<p>A meta-analysis with the aim of establishing the frequency of abnormal MRI findings in healthy individuals was published in 2009.<sup><xref ref-type="bibr" rid="bibr3-1352458512451943">3</xref></sup> It included 16 heterogeneous cohorts of 15,559 healthy adults (including the above-mentioned German study), with an unknown mean age. They reported nine cases of ‘definite demyelination’ (0.06%).</p>
<p>In 2011, Wasay and colleagues published a study conducted in Karachi, Pakistan.<sup><xref ref-type="bibr" rid="bibr23-1352458512451943">23</xref></sup> It showed that 864 persons (aged 15 to 40 years) without a previous history of MS underwent a MRI of the brain, and of these, six persons had findings that fulfilled the modified Barkhof criteria (0.7%). None of these persons had typical MS symptoms and all had a normal neurological examination. This is a surprisingly high prevalence of RIS in a referral setting in what is presumed to be a country with a low prevalence of MS.<sup><xref ref-type="bibr" rid="bibr24-1352458512451943">24</xref></sup> Unfortunately, due to the need for the patients to pay out-of-pocket for follow-up investigations, it is unclear what further investigation would have shown.</p>
<p>In conclusion, the prevalence of RIS is unknown, but it seems to be of the same order of magnitude as that previously found in post-mortem studies and in the range of 0.06–0.7%.</p>
</sec>
<sec id="section5-1352458512451943">
<title>Asymptomatic?</title>
<p>One might object that if these persons were truly neurologically asymptomatic, why were they examined with MRI? According to the published RIS cohorts, headache was by far the most common reason for performing the MRI and it seems to be the indication in about half of the cases. Other, less common, indications were trauma and endocrinological and psychiatric disorders. For a full description of reported indications, please see the supplementary appendix in the online version of this article. It is not possible to establish whether the headaches were related to the MRI findings or not. Previous studies of the prevalence of headaches in patients with MS has shown that headaches are not uncommon in MS and might be the presenting symptom in some cases of MS.<sup><xref ref-type="bibr" rid="bibr25-1352458512451943">25</xref></sup> The possibility of the headaches in RIS being an early and/or an atypical onset of demyelinating disease can therefore not be ruled out. A summary of the most common indications is presented <xref ref-type="fig" rid="fig3-1352458512451943">Figure 3</xref>.<sup><xref ref-type="bibr" rid="bibr26-1352458512451943">26</xref><xref ref-type="bibr" rid="bibr27-1352458512451943"/><xref ref-type="bibr" rid="bibr28-1352458512451943"/><xref ref-type="bibr" rid="bibr29-1352458512451943"/><xref ref-type="bibr" rid="bibr30-1352458512451943"/><xref ref-type="bibr" rid="bibr31-1352458512451943"/><xref ref-type="bibr" rid="bibr32-1352458512451943"/>–<xref ref-type="bibr" rid="bibr33-1352458512451943">33</xref></sup></p>
<fig id="fig3-1352458512451943" position="float">
<label>Figure 3.</label>
<caption>
<p>Overview of the indications for MRI in published cohorts, <italic>n</italic>=394.<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref>,<xref ref-type="bibr" rid="bibr6-1352458512451943">6</xref><xref ref-type="bibr" rid="bibr7-1352458512451943"/><xref ref-type="bibr" rid="bibr8-1352458512451943"/><xref ref-type="bibr" rid="bibr9-1352458512451943"/><xref ref-type="bibr" rid="bibr10-1352458512451943"/><xref ref-type="bibr" rid="bibr11-1352458512451943"/>–<xref ref-type="bibr" rid="bibr12-1352458512451943">12</xref>,<xref ref-type="bibr" rid="bibr23-1352458512451943">23</xref>,<xref ref-type="bibr" rid="bibr26-1352458512451943">26</xref><xref ref-type="bibr" rid="bibr27-1352458512451943"/><xref ref-type="bibr" rid="bibr28-1352458512451943"/><xref ref-type="bibr" rid="bibr29-1352458512451943"/><xref ref-type="bibr" rid="bibr30-1352458512451943"/><xref ref-type="bibr" rid="bibr31-1352458512451943"/><xref ref-type="bibr" rid="bibr32-1352458512451943"/>–<xref ref-type="bibr" rid="bibr33-1352458512451943">33</xref></sup> There are overlaps of the cohorts, which might mean that a patient has been registered more than once. For a complete description of all indications, please see the supplementary appendix in the online version of this article.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451943-fig3.tif"/></fig>
<p>Some patients in the RIS cohorts presented with cognitive impairment, which was also noted in four cases of ‘subclinical MS’ by Hakiki and colleagues.<sup><xref ref-type="bibr" rid="bibr28-1352458512451943">28</xref></sup> Cognitive impairment has later been found in two more comprehensive RIS studies with neuropsychological testing. These findings are of interest since 43–70% of MS patients have cognitive impairment.<sup><xref ref-type="bibr" rid="bibr34-1352458512451943">34</xref></sup></p>
<p>Lebrun and colleagues compared 26 persons with RIS with 26 patients with relapsing–remitting MS (RRMS), and 26 healthy controls matched with regards to age, gender and educational level.<sup><xref ref-type="bibr" rid="bibr35-1352458512451943">35</xref></sup> The persons with RIS were at high risk of developing MS since they all had dissemination in time and in space on at least two brain MRIs. The subjects were evaluated with a French adaptation of the Rao Brief Repeatable Battery (RBRB). The study showed that the results of both the RIS and RRMS groups were impaired in the Paced Auditory Serial Addition Test (PASAT) three seconds, phonemic fluencies test, digit symbol test, direct and indirect digit span tests, cross-taping test and in the Go-No-Go test. In total, 16 of the 26 persons with RIS (62%) performed at least two standard deviations below normal in at least one test. Amato and colleagues conducted a similar study and compared the results of 29 persons with RIS with the results of 26 RRMS patients and 21 healthy age- and gender-matched controls.<sup><xref ref-type="bibr" rid="bibr36-1352458512451943">36</xref></sup> The subjects were evaluated with the RBRB. Eight of 29 persons with RIS (28%) failed in at least one neuropsychological test, a proportion that did not differ significantly from the RRMS group (35%). The subjects with cognitive impairment showed a similar test profile in both groups, and on a test-by-test comparison the RRMS group only showed significantly lower cognitive performance in the PASAT two seconds and the Word List Generation Test as compared with the RIS group. It was noted that neither the persons with RIS nor their family members had noticed any signs of cognitive deficits or changes.</p>
<p>Based on these studies it seems as if cognitive impairment is common among persons with RIS, and they seem to have a similar profile of the cognitive impairment as compared with patients with RRMS.</p>
</sec>
<sec id="section6-1352458512451943">
<title>Prognosis</title>
<p>An essential question is what the prognosis of RIS is. Both MRI findings and some of its subtle symptomatology have similarities to MS. It is therefore reasonable to assume that RIS is a potential preclinical stage and/or subclinical form of MS. The characteristics of the patients in current RIS cohorts are presented in <xref ref-type="table" rid="table2-1352458512451943">Table 2</xref> and the prognostic data from these cohorts are compiled in <xref ref-type="table" rid="table3-1352458512451943">Table 3</xref>. The initial MRI characteristics, for the studies in which these have been described, are presented in <xref ref-type="table" rid="table4-1352458512451943">Table 4</xref>. In addition, data from current case reports and one mixed cohort are presented in <xref ref-type="table" rid="table5-1352458512451943">Table 5</xref>.<sup><xref ref-type="bibr" rid="bibr26-1352458512451943">26</xref><xref ref-type="bibr" rid="bibr27-1352458512451943"/><xref ref-type="bibr" rid="bibr28-1352458512451943"/><xref ref-type="bibr" rid="bibr29-1352458512451943"/>-<xref ref-type="bibr" rid="bibr30-1352458512451943">30</xref>,<xref ref-type="bibr" rid="bibr32-1352458512451943">32</xref>,<xref ref-type="bibr" rid="bibr37-1352458512451943">37</xref>,<xref ref-type="bibr" rid="bibr38-1352458512451943">38</xref></sup></p>
<table-wrap id="table2-1352458512451943" position="float">
<label>Table 2.</label>
<caption>
<p>Summary of patient characteristics from current publications of RIS cohorts.</p>
</caption>
<graphic alternate-form-of="table2-1352458512451943" xlink:href="10.1177_1352458512451943-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Study design</th>
<th align="left">Country of study</th>
<th align="left">RIS subjects, <italic>n</italic></th>
<th align="left">Age, years (range)</th>
<th align="left">Women, <italic>n</italic></th>
<th align="left">Heredity for MS, <italic>n</italic></th>
<th align="left">Path. CSF, <italic>n</italic></th>
<th align="left">Path. VEP, <italic>n</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Derwenskus and Cohen, 2007<sup><xref ref-type="bibr" rid="bibr5-1352458512451943">5</xref></sup></td>
<td>Retrospective</td>
<td>USA</td>
<td>10</td>
<td>x̄42</td>
<td>10/10</td>
<td align="left">–</td>
<td>5/8</td>
<td>2/8</td>
</tr>
<tr>
<td/>
<td>Unicentre</td>
<td/>
<td/>
<td>(30–56)</td>
<td>100%</td>
<td/>
<td>63%</td>
<td>25%</td>
</tr>
<tr>
<td>Lebrun et al., 2008<sup><xref ref-type="bibr" rid="bibr6-1352458512451943">6</xref></sup></td>
<td>Retrospective</td>
<td>France</td>
<td>30</td>
<td>x̄29</td>
<td>26/30</td>
<td>1/30</td>
<td>25/25</td>
<td>8/25</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>(16–48)</td>
<td>87%</td>
<td>3.3%</td>
<td>100%</td>
<td>32%</td>
</tr>
<tr>
<td>Okuda et al., 2009<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup></td>
<td>Retrospective</td>
<td>USA</td>
<td>44</td>
<td><italic>M</italic> 39</td>
<td>41/44</td>
<td>3/44</td>
<td>18/27</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td>Unicentre</td>
<td/>
<td/>
<td>(16–67)</td>
<td>93%</td>
<td>6.8%</td>
<td>67%</td>
<td/>
</tr>
<tr>
<td>Lebrun et al., 2009<sup><xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref></sup></td>
<td>Prospective</td>
<td>France</td>
<td>70</td>
<td>x̄36</td>
<td>53/70</td>
<td>5/70</td>
<td>35/70</td>
<td>45/70</td>
</tr>
<tr>
<td/>
<td>Multicentre</td>
<td/>
<td/>
<td>(16–48)</td>
<td>76%</td>
<td>7.1%</td>
<td>50%</td>
<td>64%</td>
</tr>
<tr>
<td>Bau et al., 2009<sup><xref ref-type="bibr" rid="bibr31-1352458512451943">31</xref></sup></td>
<td>Retrospective</td>
<td>Spain</td>
<td>13</td>
<td>x̄37</td>
<td>11/13</td>
<td>1/13</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td>Unicentre</td>
<td/>
<td/>
<td>(21–56)</td>
<td>85%</td>
<td>7.7%</td>
<td/>
<td/>
</tr>
<tr>
<td>Siva et al., 2009<sup><xref ref-type="bibr" rid="bibr8-1352458512451943">8</xref></sup></td>
<td>Prospective</td>
<td>USA, Turkey</td>
<td>22</td>
<td>x̄37 <italic>M</italic> 35</td>
<td>16/22</td>
<td>2/22</td>
<td>7/11</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td>Multicentre</td>
<td/>
<td/>
<td>(17–70)</td>
<td>73%</td>
<td>9.1%</td>
<td>64%</td>
<td/>
</tr>
<tr>
<td>Sierra-Marcos et al., 2010<sup><xref ref-type="bibr" rid="bibr9-1352458512451943">9</xref></sup></td>
<td>Retrospective</td>
<td>Spain</td>
<td>11</td>
<td>x̄36</td>
<td>7/11</td>
<td>1/11</td>
<td>6/11</td>
<td>3/9</td>
</tr>
<tr>
<td/>
<td>Unicentre</td>
<td/>
<td/>
<td>(28–48)</td>
<td>64%</td>
<td>9.1%</td>
<td>55%</td>
<td>33%</td>
</tr>
<tr>
<td>Lebrun et al., 2010<sup><xref ref-type="bibr" rid="bibr35-1352458512451943">35</xref></sup></td>
<td>Prospective</td>
<td>France</td>
<td>26</td>
<td>x̄40</td>
<td>23/26</td>
<td align="left">–</td>
<td>24/26</td>
<td>25/26</td>
</tr>
<tr>
<td/>
<td>Multicentre</td>
<td/>
<td/>
<td>(18–52)</td>
<td>88%</td>
<td/>
<td>92%</td>
<td>96%</td>
</tr>
<tr>
<td>De Stefano et al., 2011<sup><xref ref-type="bibr" rid="bibr33-1352458512451943">33</xref></sup></td>
<td>Retrospective</td>
<td>Italy</td>
<td>19</td>
<td>x̄37</td>
<td>14/19</td>
<td align="left">–</td>
<td>10/15</td>
<td>3/15</td>
</tr>
<tr>
<td/>
<td>Unicentre</td>
<td/>
<td/>
<td>(19–51)</td>
<td>74%</td>
<td/>
<td>67%</td>
<td>20%</td>
</tr>
<tr>
<td>Okuda et al., 2011<sup><xref ref-type="bibr" rid="bibr10-1352458512451943">10</xref></sup></td>
<td>Retrospective</td>
<td>USA</td>
<td>71</td>
<td><italic>M</italic> 38</td>
<td>56/71</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td>Unicentre</td>
<td/>
<td/>
<td align="left">–</td>
<td>79%</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Maia et al., 2012<sup><xref ref-type="bibr" rid="bibr11-1352458512451943">11</xref></sup></td>
<td>Retrospective</td>
<td>Brazil</td>
<td>12</td>
<td>x̄39</td>
<td>10/12</td>
<td>0/12</td>
<td>2/2</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td>Multicentre</td>
<td/>
<td/>
<td>(17–54)</td>
<td>83%</td>
<td>0%</td>
<td>100%</td>
<td/>
</tr>
<tr>
<td>Lebrun et al., 2012<sup><xref ref-type="bibr" rid="bibr12-1352458512451943">12</xref></sup></td>
<td>Prospective</td>
<td>France</td>
<td>60</td>
<td>x̄30</td>
<td>60/60</td>
<td align="left">–</td>
<td>31/60</td>
<td>24/60</td>
</tr>
<tr>
<td/>
<td>Multicentre</td>
<td/>
<td/>
<td>(22–46)</td>
<td>100%</td>
<td/>
<td>52%</td>
<td>40%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1352458512451943"><p>x̄: mean; <italic>M</italic>: median; –: not relevant or no information available; Path. CSF: presence of oligoclonal bands in the cerebrospinal fluid and/or pathologically raised IgG index; Path. VEP: abnormal latencies on VEP</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1352458512451943" position="float">
<label>Table 3.</label>
<caption>
<p>Summary of the prognostic data from current publications of RIS cohorts.</p>
</caption>
<graphic alternate-form-of="table3-1352458512451943" xlink:href="10.1177_1352458512451943-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Observation period, years (range)</th>
<th align="left">MRI criteria</th>
<th align="left">Initial radiological DIS</th>
<th align="left">rDIT, <italic>n</italic></th>
<th align="left">Time to rDIT, years (range)</th>
<th align="left">Clinical conversion, <italic>n</italic></th>
<th align="left">Time to clinical conversion, years (range)</th>
<th align="left">CIS, <italic>n</italic></th>
<th align="left">Time to CIS, years (range)</th>
<th align="left">CDMS, subtype (<italic>n</italic>)</th>
<th align="left">Time to CDMS, years (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2">Derwenskus and Cohen, 2007<sup><xref ref-type="bibr" rid="bibr5-1352458512451943">5</xref></sup></td>
<td>x̄ 2.5</td>
<td>Barkhof</td>
<td>100%</td>
<td>3/10</td>
<td align="left">–</td>
<td>3/6</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td>Unsp. (3)</td>
<td align="left">–</td>
</tr>
<tr>
<td>(0–5.9)</td>
<td/>
<td/>
<td>30%</td>
<td/>
<td>50%</td>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td rowspan="2">Lebrun et al., 2008<sup><xref ref-type="bibr" rid="bibr6-1352458512451943">6</xref></sup></td>
<td align="left">–</td>
<td>Barkhof-Tintoré?</td>
<td align="left">–</td>
<td>25/30</td>
<td>&lt;2.0<xref ref-type="table-fn" rid="table-fn3-1352458512451943">*</xref></td>
<td>11/30</td>
<td>x̄2.3</td>
<td>11/30</td>
<td>x̄2.3</td>
<td>Unsp. (3)</td>
<td align="left">–</td>
</tr>
<tr>
<td>(0.8–5.0)</td>
<td/>
<td/>
<td>83%</td>
<td/>
<td>37%</td>
<td>(0.8–5.0)</td>
<td>37%</td>
<td>(0.8–5.0)</td>
<td/>
<td/>
</tr>
<tr>
<td rowspan="2">Okuda et al., 2009<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup></td>
<td align="left">–</td>
<td>Barkhof</td>
<td>100%</td>
<td>24/41</td>
<td><italic>M</italic> 2.7</td>
<td>10/30</td>
<td><italic>M</italic> 5.4</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td>(0.1–26)</td>
<td/>
<td/>
<td>59%</td>
<td>(0.1–26.0)</td>
<td>33%</td>
<td>(1.1–9.8)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td rowspan="2">Lebrun et al., 2009<sup><xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref></sup></td>
<td>x̄ 5.2</td>
<td>Barkhof-Tintoré</td>
<td>56/70</td>
<td>64/70</td>
<td align="left">–</td>
<td>23/70</td>
<td>x̄2.3</td>
<td>23/70</td>
<td>x̄2.3</td>
<td>RRMS (8)</td>
<td>x̄3.1</td>
</tr>
<tr>
<td>(3.0–6.4)</td>
<td/>
<td>80%</td>
<td>91%</td>
<td/>
<td>33%</td>
<td>(0.8–5.0)</td>
<td>33%</td>
<td>(0.8–5.0)</td>
<td/>
<td align="left">–</td>
</tr>
<tr>
<td rowspan="2">Bau et al., 2009<sup><xref ref-type="bibr" rid="bibr31-1352458512451943">31</xref></sup></td>
<td>x̄ 3.0</td>
<td>Barkhof</td>
<td>9/13</td>
<td align="left">–</td>
<td align="left">–</td>
<td>2/13</td>
<td>6</td>
<td align="left">–</td>
<td align="left">–</td>
<td>Unsp. (2)</td>
<td>6</td>
</tr>
<tr>
<td align="left">–</td>
<td/>
<td>69%</td>
<td>27%</td>
<td/>
<td>15%</td>
<td>(1–11)</td>
<td/>
<td/>
<td/>
<td>(1–11)</td>
</tr>
<tr>
<td rowspan="2">Siva et al. 2009<sup><xref ref-type="bibr" rid="bibr8-1352458512451943">8</xref></sup></td>
<td>M 2.5</td>
<td>Barkhof-Tintoré</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td>8/22</td>
<td><italic>M</italic> 2.4</td>
<td align="left">–</td>
<td align="left">–</td>
<td>Unsp. (8)</td>
<td>M 2.4</td>
</tr>
<tr>
<td>(0.8–12.5)</td>
<td/>
<td/>
<td/>
<td/>
<td>36%</td>
<td>(0.2–9.3)</td>
<td/>
<td/>
<td/>
<td>(0.2–9.3)</td>
</tr>
<tr>
<td rowspan="2">Sierra-Marcos et al., 2010<sup><xref ref-type="bibr" rid="bibr9-1352458512451943">9</xref></sup></td>
<td>x̄2.9</td>
<td>Barkhof-Tintoré</td>
<td>10/11</td>
<td>7/11</td>
<td>x̄2.5</td>
<td>5/11</td>
<td>x̄4.1</td>
<td>5/11</td>
<td>x̄4.1</td>
<td>RRMS (2)</td>
<td>x̄8.5</td>
</tr>
<tr>
<td>(0.1–11.6)</td>
<td/>
<td>91%</td>
<td>64%</td>
<td>(0.4–4.0)</td>
<td>45%</td>
<td>(0.2–13)</td>
<td>45%</td>
<td>(0.2–13)</td>
<td>PPMS (1)</td>
<td>(4–13)</td>
</tr>
<tr>
<td rowspan="2">De Stefano et al., 2011<sup><xref ref-type="bibr" rid="bibr33-1352458512451943">33</xref></sup></td>
<td>x̄2.4</td>
<td>Barkhof</td>
<td>19/19</td>
<td>10/19</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td>(0.1–7.0)</td>
<td/>
<td>100%</td>
<td>53%</td>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td rowspan="2">Okuda et al., 2011<sup><xref ref-type="bibr" rid="bibr10-1352458512451943">10</xref></sup></td>
<td>M ≈3</td>
<td>Barkhof</td>
<td>71/71</td>
<td align="left">–</td>
<td align="left">–</td>
<td>24/71</td>
<td align="left">–</td>
<td>22/71</td>
<td align="left">–</td>
<td>PPMS (2)</td>
<td align="left">–</td>
</tr>
<tr>
<td align="left">–</td>
<td/>
<td>100%</td>
<td/>
<td/>
<td>34%</td>
<td>(0.8–9.8)</td>
<td>31%</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td rowspan="2">Maia et al., 2012<sup><xref ref-type="bibr" rid="bibr11-1352458512451943">11</xref></sup></td>
<td>x̄4.1</td>
<td>Barkhof</td>
<td>100%</td>
<td>6/12</td>
<td align="left">–</td>
<td>4/12</td>
<td>x̄
 3.0</td>
<td>2/12</td>
<td>2/12</td>
<td>RRMS (2)</td>
<td align="left">–</td>
</tr>
<tr>
<td>(0.9–9.1)</td>
<td/>
<td/>
<td>50%</td>
<td/>
<td>33%</td>
<td>(0.6–5.9)</td>
<td>42%</td>
<td>42%</td>
<td/>
<td/>
</tr>
<tr>
<td rowspan="2">Lebrun et al., 2012<sup><xref ref-type="bibr" rid="bibr12-1352458512451943">12</xref></sup></td>
<td>x̄ 7</td>
<td>Barkhof-Tintoré</td>
<td>45/60</td>
<td>48/60</td>
<td>x̄0.6</td>
<td>26/60</td>
<td>x̄2.7</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td>(2.3–8.9)</td>
<td/>
<td>75%</td>
<td>80%</td>
<td>(0.3–1.3)</td>
<td>43%</td>
<td>(0.7–6.3)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458512451943">
<label>*</label>
<p>17 patients progressed radiologically within one year and seven patients within one to two years.</p></fn>
<fn id="table-fn4-1352458512451943"><p>CIS: clinically isolated syndrome; CDMS: clinically definite multiple sclerosis; RRMS: relapsing–remitting multiple sclerosis; PPMS: primary-progressive multiple sclerosis; x̄: mean; <italic>M</italic>: median; –: not relevant or no information available; Unsp.: unspecified: DIS: dissemination in space: rDIT: radiological dissemination in time</p></fn>
</table-wrap-foot></table-wrap>
<table-wrap id="table4-1352458512451943" position="float">
<label>Table 4.</label>
<caption>
<p>Summary of the specified characteristics of MRI findings on initial MRI.</p>
</caption>
<graphic alternate-form-of="table4-1352458512451943" xlink:href="10.1177_1352458512451943-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Gadolinium- enhanced lesion(s)</th>
<th align="left">&gt;9 T<sub>2</sub> hyper- intensities</th>
<th align="left">Infratentorial lesion(s)</th>
<th align="left">Spinal cord lesion(s)</th>
<th align="left">Juxtacortical lesion(s)</th>
<th align="left">≥3 peri-ventricular lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lebrun et al., 2008<sup><xref ref-type="bibr" rid="bibr6-1352458512451943">6</xref></sup></td>
<td>9/30</td>
<td>21/30</td>
<td>10/30</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td>(30%)</td>
<td>(70%)</td>
<td>(33%)</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Hakiki et al., 2008<sup><xref ref-type="bibr" rid="bibr28-1352458512451943">28</xref></sup></td>
<td align="left">–</td>
<td>4/4</td>
<td>2/4</td>
<td align="left">–</td>
<td>2/4</td>
<td>4/4</td>
</tr>
<tr>
<td/>
<td/>
<td>(100%)</td>
<td>(50%)</td>
<td/>
<td>(50%)</td>
<td>(100%)</td>
</tr>
<tr>
<td>Okuda et al., 2009<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup></td>
<td>10/41</td>
<td>44/44</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td>(24%)</td>
<td>(100%)</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Lebrun et al., 2009<sup><xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref></sup></td>
<td>17/70</td>
<td>63/70</td>
<td>45/7</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td>(24%)</td>
<td>(90%)</td>
<td>(64%)</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Maia et al., 2012<sup><xref ref-type="bibr" rid="bibr11-1352458512451943">11</xref></sup></td>
<td>4/12</td>
<td>11/12</td>
<td>6/12</td>
<td>5/12</td>
<td>12/12</td>
<td>11/12</td>
</tr>
<tr>
<td/>
<td>(33%)</td>
<td>(92%)</td>
<td>(50%)</td>
<td>(42%)</td>
<td>(100%)</td>
<td>(92%)</td>
</tr>
<tr>
<td>Lebrun et al., 2012<sup><xref ref-type="bibr" rid="bibr12-1352458512451943">12</xref></sup></td>
<td>13/60</td>
<td>49/60</td>
<td>17/60</td>
<td>18/60</td>
<td>60/60</td>
<td>60/60</td>
</tr>
<tr>
<td/>
<td>(22%)</td>
<td>(82%)</td>
<td>(28%)</td>
<td>(30%)</td>
<td>(100%)</td>
<td>(100%)</td>
</tr>
</tbody>
</table></table-wrap>
<table-wrap id="table5-1352458512451943" position="float">
<label>Table 5.</label>
<caption>
<p>Single case reports and mixed cohorts.</p>
</caption>
<graphic alternate-form-of="table5-1352458512451943" xlink:href="10.1177_1352458512451943-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">McDonnell et al., 2003<sup><xref ref-type="bibr" rid="bibr26-1352458512451943">26</xref></sup></th>
<th align="left">De Seze et al., 2005<sup><xref ref-type="bibr" rid="bibr27-1352458512451943">27</xref></sup></th>
<th align="left">Eraksoy et al., 2007<sup><xref ref-type="bibr" rid="bibr37-1352458512451943">37</xref></sup>
<xref ref-type="table-fn" rid="table-fn5-1352458512451943">*</xref></th>
<th align="left">Hakiki et al., 2008<sup><xref ref-type="bibr" rid="bibr28-1352458512451943">28</xref></sup></th>
<th align="left">Sempere et al., 2009<sup><xref ref-type="bibr" rid="bibr38-1352458512451943">38</xref></sup></th>
<th align="left">Mäurer, 2009<sup><xref ref-type="bibr" rid="bibr29-1352458512451943">29</xref></sup></th>
<th align="left">Meuth et al., 2009<sup><xref ref-type="bibr" rid="bibr30-1352458512451943">30</xref></sup></th>
<th align="left">Spain and Bourdette, 2011<sup><xref ref-type="bibr" rid="bibr32-1352458512451943">32</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Country of study</td>
<td>Canada</td>
<td>France</td>
<td>Turkey</td>
<td>Italy</td>
<td>Spain</td>
<td>Germany</td>
<td>Germany</td>
<td>USA</td>
</tr>
<tr>
<td>RIS subjects, <italic>n</italic></td>
<td>1</td>
<td>1</td>
<td>22</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Age, year (range)</td>
<td>39</td>
<td>34</td>
<td align="left">–</td>
<td>x̄
 37</td>
<td>39</td>
<td>24</td>
<td>31</td>
<td>x̄ 35</td>
</tr>
<tr>
<td/>
<td align="left">–</td>
<td align="left">–</td>
<td>(13–74)</td>
<td>(32–40)</td>
<td align="left">–</td>
<td/>
<td/>
<td>(27 and 42)</td>
</tr>
<tr>
<td>Female/females, <italic>n</italic></td>
<td>No</td>
<td>Yes</td>
<td>13/22</td>
<td>2/4</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>1/2</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>59%</td>
<td>50%</td>
<td/>
<td/>
<td/>
<td>50%</td>
</tr>
<tr>
<td>Heredity for MS, <italic>n</italic></td>
<td align="left">–</td>
<td align="left">–</td>
<td>4/22</td>
<td>1/4</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>18%</td>
<td>25%</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>MRI criteria</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td>Barkhof-Tintoré</td>
<td align="left">–</td>
<td>Barkhof</td>
<td>Barkhof</td>
<td>Barkhof-Tintoré</td>
</tr>
<tr>
<td>Initial radiological DIS, <italic>n</italic></td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td>4/4</td>
<td align="left">–</td>
<td>Yes</td>
<td>Yes</td>
<td>2/2</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>100 %</td>
<td/>
<td/>
<td/>
<td>100 %</td>
</tr>
<tr>
<td>Path. CSF, <italic>n</italic></td>
<td>No</td>
<td>Yes</td>
<td>10/12</td>
<td>2/3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2/2</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>83%</td>
<td>67%</td>
<td/>
<td/>
<td/>
<td>100%</td>
</tr>
<tr>
<td>Path. VEP, <italic>n</italic></td>
<td align="left">–</td>
<td>Yes</td>
<td align="left">–</td>
<td>2/4</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td align="left">–</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>50%</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Observation period, years (range)</td>
<td>10</td>
<td>4.4</td>
<td>~ 3</td>
<td>x̄
 6.7</td>
<td>2.3</td>
<td align="left">–</td>
<td align="left">–</td>
<td>x̄ 5</td>
</tr>
<tr>
<td/>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td>(5–8)</td>
<td align="left">–</td>
<td/>
<td/>
<td>(2 and 8)</td>
</tr>
<tr>
<td>rDIT, <italic>n</italic></td>
<td>Yes</td>
<td>Yes</td>
<td>11/22</td>
<td>2/4</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>2/2</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>50%</td>
<td>50%</td>
<td/>
<td/>
<td/>
<td>100%</td>
</tr>
<tr>
<td>Time to rDIT, years (range)</td>
<td>5</td>
<td align="left">–</td>
<td align="left">–</td>
<td>1.5</td>
<td>2</td>
<td>1</td>
<td>0.1</td>
<td>x̄
 5</td>
</tr>
<tr>
<td/>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td>(1–2)</td>
<td align="left">–</td>
<td align="left">–</td>
<td align="left">–</td>
<td>(2 and 8)</td>
</tr>
<tr>
<td>Clinical conversion, <italic>n</italic></td>
<td>Yes</td>
<td>Yes</td>
<td>10/22</td>
<td>1/4</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>1/2</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>45%</td>
<td>25%</td>
<td/>
<td/>
<td/>
<td>50%</td>
</tr>
<tr>
<td>Time to clinical conversion, years (clinical diagnosis)</td>
<td>8.5 (PPMS)</td>
<td>3.7 (CDMS)</td>
<td>– (CDMS)</td>
<td>3 (CIS)</td>
<td>2.3 (CIS)</td>
<td>1.8 (CIS)</td>
<td>1 (CDMS)</td>
<td>2 (PPMS)</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>4 (RRMS)</td>
<td>4.3 (RRMS)</td>
<td/>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1352458512451943">
<label>*</label>
<p>Five of these patients had neurological symptoms.</p></fn>
<fn id="table-fn6-1352458512451943"><p>RIS: radiologically isolated syndrome; MS: multiple sclerosis; x̄: mean; <italic>M</italic>: median; –: not relevant or no information available; Path. CSF: presence of oligoclonal bands in the cerebrospinal fluid and/or pathologically raised IgG index; Path. VEP: abnormal latencies on VEP: DIS = dissemination in space; rDIT: radiological dissemination in time; PPMS: primary-progressive multiple sclerosis; CDMS: clinically definite multiple sclerosis; CIS: clinically isolated syndrome; RRMS: relapsing–remitting multiple sclerosis</p></fn>
</table-wrap-foot>
</table-wrap>
<p>The results of the studies in <xref ref-type="table" rid="table2-1352458512451943">Tables 2</xref><xref ref-type="table" rid="table3-1352458512451943"/><xref ref-type="table" rid="table4-1352458512451943"/>–<xref ref-type="table" rid="table5-1352458512451943">5</xref> are not directly comparable due to differences in study methodology. There is also a probable overlap in studied cohorts, which implies that the total number of studied persons with RIS is lower. The time to radiological progression is dependent on when follow up MRI examinations are performed. All subjects in the study by Lebrun and colleagues in 2012 were female because of the study’s aim of evaluating the significance of pregnancy on the prognosis of RIS.<sup><xref ref-type="bibr" rid="bibr12-1352458512451943">12</xref></sup> The RIS cohort presented by Giorgio and colleagues,<sup><xref ref-type="bibr" rid="bibr39-1352458512451943">39</xref></sup> was omitted due to its inclusion in the study by De Stefano and colleagues.<sup><xref ref-type="bibr" rid="bibr33-1352458512451943">33</xref></sup> Amato and colleagues described a larger cohort<sup><xref ref-type="bibr" rid="bibr36-1352458512451943">36</xref></sup> that probably overlaps with the cohort by De Stefano and colleagues and Giorgio and colleagues, but that study did not provide prognostic data and was therefore not included in <xref ref-type="table" rid="table2-1352458512451943">Tables 2</xref> and <xref ref-type="table" rid="table3-1352458512451943">3</xref>.</p>
<p>The studies in <xref ref-type="table" rid="table2-1352458512451943">Tables 2</xref> and <xref ref-type="table" rid="table3-1352458512451943">3</xref> show that during mean follow-up times in the range of two to five years, a majority of persons with RIS progress radiologically with new lesions and/or gadolinium enhancement on MRI. During the same time period approximately one-third develops symptoms characteristic of MS and thereby convert to CIS and/or MS. The patients with MS progressed to both RRMS and primary-progressive MS (PPMS) subtypes.</p>
<p>Demographically, it is noteworthy that the mean age is around the mid-thirties, but with a range from late teens up to 70 years of age. This stresses the need to rule out other underlying causes for white matter hyperintensities such as vascular degenerative changes.</p>
<p>The studies in <xref ref-type="table" rid="table2-1352458512451943">Tables 2</xref> and <xref ref-type="table" rid="table3-1352458512451943">3</xref> suggest the following predictors for both radiological and clinical progression of RIS:</p>
<disp-quote>
<p>More than nine T<sub>2</sub>-lesions;<sup><xref ref-type="bibr" rid="bibr6-1352458512451943">6</xref>,<xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref></sup></p>
<p>Gadolinium contrast medium enhancing lesions;<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref>,<xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref></sup> however, this could not be confirmed in another, smaller, study.<sup><xref ref-type="bibr" rid="bibr11-1352458512451943">11</xref></sup></p>
</disp-quote>
<p>The following predictors increase the risk of clinical progression:</p>
<disp-quote>
<p>Cervical spine lesions;<sup><xref ref-type="bibr" rid="bibr10-1352458512451943">10</xref></sup></p>
<p>Infratentorial lesions;<sup><xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref>,<xref ref-type="bibr" rid="bibr10-1352458512451943">10</xref>,<xref ref-type="bibr" rid="bibr11-1352458512451943">11</xref></sup></p>
<p>A higher number of lesions;<sup><xref ref-type="bibr" rid="bibr11-1352458512451943">11</xref></sup></p>
<p>Pathological VEP;<sup><xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref></sup></p>
<p>Younger age;<sup><xref ref-type="bibr" rid="bibr10-1352458512451943">10</xref></sup></p>
<p>Oligoclonal bands and/or a pathological IgG index in combination with more than nine T<sub>2</sub>-lesions on the initial MRI examination;<sup><xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref></sup></p>
<p>Pregnancy shortened the time to clinical conversion in those who developed MS.<sup><xref ref-type="bibr" rid="bibr12-1352458512451943">12</xref></sup></p>
</disp-quote>
<p>Of these predictors, cervical spinal cord lesions were identified as especially important because of their high sensitivity, specificity and positive predictive value for clinical conversion.<sup><xref ref-type="bibr" rid="bibr10-1352458512451943">10</xref></sup></p>
<p>In the study by De Stefano and colleagues non-conventional MRI methods in the form of magnetic transfer measurements and volumetric measurements were used in order to improve the characterisation of RIS. This showed that not only do patients with RIS and RRMS have a similar lesion volume and lesion distribution, but they also have similar low brain volumes in comparison with healthy controls.<sup><xref ref-type="bibr" rid="bibr33-1352458512451943">33</xref></sup> These results strengthen the association of RIS and MS, and show that this kind of radiological data might be useful in stratifying which persons with RIS are at risk of developing MS.</p>
</sec>
<sec id="section7-1352458512451943">
<title>Management</title>
<p>The management of RIS is controversial.<sup><xref ref-type="bibr" rid="bibr40-1352458512451943">40</xref></sup> MS-like findings without a clinical correlation are troublesome for both the patient and the physician, due to the uncertain prognosis and the possibility of progression to MS.<sup><xref ref-type="bibr" rid="bibr41-1352458512451943">41</xref></sup> The first step of management is to exclude other differential diagnoses.<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref>,<xref ref-type="bibr" rid="bibr42-1352458512451943">42</xref></sup> The consensus report from an international panel of MS experts is helpful in identifying or excluding differential diagnoses.<sup><xref ref-type="bibr" rid="bibr43-1352458512451943">43</xref></sup> A careful clinical history and a thorough clinical examination are mandatory. The investigation has to be individualised depending on the patient and available resources. Tactful information to, and continuous dialogue with, the patient is of essence.<sup><xref ref-type="bibr" rid="bibr41-1352458512451943">41</xref></sup></p>
<p>There are three basic approaches to RIS management: wait, follow or treat. Sellner and colleagues have proposed an algorithm for the wait and follow strategies.<sup><xref ref-type="bibr" rid="bibr42-1352458512451943">42</xref></sup> <italic>Wait</italic> implies a conservative and passive approach, with no further follow-ups planned, but the patient is instructed to seek healthcare if symptoms occur. This strategy has the advantage of not burdening the patient with potentially unnecessary follow-ups. <italic>Follow</italic> constitutes a more active approach with planned clinical and radiological follow-ups, with the first control suggested after six months and a possible second control after approximately 24 months.<sup><xref ref-type="bibr" rid="bibr42-1352458512451943">42</xref></sup> Seeing how important cervical spinal cord lesions are for the clinical prognosis, imaging of at least the cervical medulla is recommended.<sup><xref ref-type="bibr" rid="bibr10-1352458512451943">10</xref></sup> One key feature of the follow algorithm is that CSF analysis is not performed until there has been a proven dissemination in time radiologically, or after a clinical event.<sup><xref ref-type="bibr" rid="bibr42-1352458512451943">42</xref></sup> On the other hand, Lebrun and colleagues proposed in 2009 that paraclinical examinations should be proposed already after the initial scan that fulfilled the Barkhof-Tintoré criteria.<sup><xref ref-type="bibr" rid="bibr7-1352458512451943">7</xref></sup></p>
<p>Finally, <italic>treat</italic> is a highly controversial option that implies that disease modifying therapy (DMT) is initiated in RIS.<sup><xref ref-type="bibr" rid="bibr40-1352458512451943">40</xref></sup> The efficacy of early initiation of DMT in RRMS has been confirmed in randomised controlled trials, and in CIS DMT has been shown to delay the conversion to MS.<sup><xref ref-type="bibr" rid="bibr44-1352458512451943">44</xref></sup> Whether DMT is beneficial in a longer perspective is, however, more uncertain and the potential benefits in RIS remain hypothetical,<sup><xref ref-type="bibr" rid="bibr32-1352458512451943">32</xref>,<xref ref-type="bibr" rid="bibr42-1352458512451943">42</xref></sup> especially since some of these persons will not develop a clinical event despite relatively long follow-up times.<sup><xref ref-type="bibr" rid="bibr8-1352458512451943">8</xref>,<xref ref-type="bibr" rid="bibr11-1352458512451943">11</xref>,<xref ref-type="bibr" rid="bibr32-1352458512451943">32</xref></sup> Studies presented in <xref ref-type="table" rid="table6-1352458512451943">Table 6</xref> nevertheless show that some of the persons with RIS have received off-label DMT. This is controversial because it has not been studied in any treatment trials and because of the potentially serious side-effects of DMT.<sup><xref ref-type="bibr" rid="bibr40-1352458512451943">40</xref></sup> Since the patient per definition is virtually neurologically asymptomatic and may not develop clinical symptoms, and with no evidence to support DMTs in RIS, this approach is generally not recommended.<sup><xref ref-type="bibr" rid="bibr45-1352458512451943">45</xref>,<xref ref-type="bibr" rid="bibr46-1352458512451943">46</xref></sup></p>
<table-wrap id="table6-1352458512451943" position="float">
<label>Table 6.</label>
<caption>
<p>Proportion of persons with RIS on disease modifying therapy (DMT).</p>
</caption>
<graphic alternate-form-of="table6-1352458512451943" xlink:href="10.1177_1352458512451943-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Patients on DMT, <italic>n</italic></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lebrun et al., 2008<sup><xref ref-type="bibr" rid="bibr6-1352458512451943">6</xref></sup></td>
<td>3/30</td>
</tr>
<tr>
<td>Okuda et al., 2009<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup></td>
<td>7/44</td>
</tr>
<tr>
<td>Meuth et al., 2009<sup><xref ref-type="bibr" rid="bibr30-1352458512451943">30</xref></sup></td>
<td>1/1</td>
</tr>
<tr>
<td>Sempere et al., 2009<sup><xref ref-type="bibr" rid="bibr38-1352458512451943">38</xref></sup></td>
<td>1/1</td>
</tr>
<tr>
<td>Sierra-Marcos et al., 2010<sup><xref ref-type="bibr" rid="bibr9-1352458512451943">9</xref></sup></td>
<td>0/11</td>
</tr>
<tr>
<td>Siva et al., 2009<sup><xref ref-type="bibr" rid="bibr8-1352458512451943">8</xref></sup></td>
<td>0/22</td>
</tr>
<tr>
<td>Spain and Bourdette, 2011<sup><xref ref-type="bibr" rid="bibr32-1352458512451943">32</xref></sup></td>
<td>0/2</td>
</tr>
<tr>
<td>Okuda et al., 2011<sup><xref ref-type="bibr" rid="bibr10-1352458512451943">10</xref></sup></td>
<td>7/71</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Regardless of approach, one has to take into account what the indication for the MRI was and try to alleviate any symptoms (i.e. headache) that the patient might have.<sup><xref ref-type="bibr" rid="bibr41-1352458512451943">41</xref></sup> With regard to the high frequencies of cognitive impairment in RIS, neuropsychological testing is also suggested to detect subclinical cognitive deficits where support might be needed.<sup><xref ref-type="bibr" rid="bibr36-1352458512451943">36</xref></sup> In accordance with the recent BICAMS study, the Symbol Digit Modalities Test is recommended as a first-hand option in a clinical setting and, if time permits, more comprehensive testing can be done with the second edition of the California Verbal Learning Test and the Brief Visuospatial Memory Test.<sup><xref ref-type="bibr" rid="bibr34-1352458512451943">34</xref></sup></p>
</sec>
<sec id="section8-1352458512451943">
<title>Future studies</title>
<p>Since the follow-up periods of the present available studies of RIS cohorts are relative short in the context of the risk of developing MS, longer prospective studies are needed in order to further investigate the long-term risk and prognostic factors for clinical conversion. This is necessary for the evaluation of the current criteria for RIS and for the identification of important predictors of radiological progression and/or clinical conversion. It will also aid in defining the role of DMT in RIS, so that randomised controlled trials can possibly be considered in high-risk populations. For comparison, future studies should implement the Okuda criteria<sup><xref ref-type="bibr" rid="bibr4-1352458512451943">4</xref></sup> and validate them. Further research is needed to evaluate the implication of new MRI criteria for classification of dissemination in space and time on RIS,<sup><xref ref-type="bibr" rid="bibr32-1352458512451943">32</xref></sup> such as the Swanton and MAGNIMS criteria.<sup><xref ref-type="bibr" rid="bibr47-1352458512451943">47</xref></sup> The use of non-conventional MRI methods such as magnetisation transfer and volumetry have shown promising results in risk stratification in small samples, why studies with focus on those and other non-conventional methods such as diffusion imaging, magnetic resonance spectroscopy and relaxometry will be of interest. Lastly, with regards to the subclinical cognitive impairment of RIS, quality of life studies of RIS would be of great value in order to establish the impact of RIS on everyday life. Considering the interest that RIS has attracted and with on-going research at many different sites, we anticipate interesting results in the near future.</p>
</sec>
<sec id="section9-1352458512451943" sec-type="conclusions">
<title>Conclusions</title>
<p>This systematic review summarises the current data on RIS. Due to differences in study methodology and an overlap of the published RIS cohorts, the data are not directly comparable and do not permit any meta-analyses. However, this review shows that approximately half of the persons had their first MRI examination because of headache. There is often a subclinical cognitive impairment in persons with RIS, similar to that seen in RRMS, and radiological measurements show a similarity between RIS and RRMS compared with healthy controls. Approximately two-thirds show a radiological progression on subsequent MRI examination, and from a clinical perspective roughly one-third shows a clinical conversion to CIS and/or MS in cohorts with a range of mean follow-up times of two to five years. Cervical spine lesions have been identified as especially important predictors for clinical conversion. Management is still a matter of debate but there are two generally accepted approaches: <italic>wait</italic> and <italic>follow</italic>. This has to be individualised depending on available resources, the physician's and the patient's views as well as the presence of prognostic factors for clinical progression, with spinal cord lesions being an especially important finding. Some patients receive DMT, although the effects of such treatment have not been studied. Initiation of DMT is not recommended outside of prospective controlled treatment trials. Future studies should try to validate the current RIS criteria and answer fundamental questions regarding the prevalence and long-term prognosis of RIS, the impact of RIS on quality of life and the role of DMT in RIS.</p>
</sec>
</body>
<back>
<ack><p>We thank Dr Karin Johnsson for valuable comments on an earlier version of this systematic review.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>Sten Fredrikson has received honoraria for lectures or educational activities from Allergan, Bayer, BiogenIdec, Merck Serono, Sanofi and Teva. All other authors declare no conflicts of interest.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512451943">
<label>1.</label>
<citation citation-type="book">
<collab>World Health Organization</collab>. <source>Environmental Health Criteria 232 – Static fields</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>, <year>2006</year>.</citation>
</ref>
<ref id="bibr2-1352458512451943">
<label>2.</label>
<citation citation-type="web">
<collab>The Organisation for Economic Co-operation and Development</collab>. <source>OECD Health Data 2011</source>, <comment><ext-link ext-link-type="uri" xlink:href="http://www.oecd.org/dataoecd/52/42/48304068.xls">http://www.oecd.org/dataoecd/52/42/48304068.xls</ext-link></comment> (<year>2011</year>, <access-date>accessed 5 March 2012</access-date>).</citation>
</ref>
<ref id="bibr3-1352458512451943">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>Z</given-names></name>
<name><surname>Whiteley</surname><given-names>WN</given-names></name>
<name><surname>Longstreth</surname><given-names>WT</given-names><suffix>Jr</suffix></name>
<etal/>
</person-group>. <article-title>Incidental findings on brain magnetic resonance imaging: Systematic review and meta-analysis</article-title>. <source>BMJ</source> <year>2009</year>; <volume>339</volume>: <fpage>b3016</fpage>.</citation>
</ref>
<ref id="bibr4-1352458512451943">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okuda</surname><given-names>DT</given-names></name>
<name><surname>Mowry</surname><given-names>EM</given-names></name>
<name><surname>Beheshtian</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome</article-title>. <source>Neurology</source> <year>2009</year>; <volume>72</volume>: <fpage>800</fpage>–<lpage>805</lpage>. <comment><italic>Erratum: Neurology</italic> 2009; 73: 1714.</comment></citation>
</ref>
<ref id="bibr5-1352458512451943">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Derwenskus</surname><given-names>J</given-names></name>
<name><surname>Cohen</surname><given-names>BA.</given-names></name>
</person-group> <article-title>Clinically silent multiple sclerosis: Description of a patient cohort without symptoms typical of MS but abnormal brain magnetic resonance imaging</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>: <fpage>1226</fpage>–<lpage>1227</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512451943">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lebrun</surname><given-names>C</given-names></name>
<name><surname>Bensa</surname><given-names>C</given-names></name>
<name><surname>Debouverie</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Unexpected multiple sclerosis: Follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2008</year>; <volume>79</volume>: <fpage>195</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512451943">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lebrun</surname><given-names>C</given-names></name>
<name><surname>Bensa</surname><given-names>C</given-names></name>
<name><surname>Debouverie</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: Follow-up of 70 patients</article-title>. <source>Arch Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>841</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512451943">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siva</surname><given-names>A</given-names></name>
<name><surname>Saip</surname><given-names>S</given-names></name>
<name><surname>Altintas</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>918</fpage>–<lpage>927</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512451943">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sierra-Marcos</surname><given-names>A</given-names></name>
<name><surname>Mitjana</surname><given-names>R</given-names></name>
<name><surname>Castilló</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Demyelinating lesions as incidental findings in magnetic resonance imaging: A study of 11 cases with clinico-radiological follow-up and a review of the literature</article-title>. <source>Rev Neurol</source> <year>2010</year>; <volume>51</volume>: <fpage>129</fpage>–<lpage>134</lpage>. (<comment>Spanish</comment>)</citation>
</ref>
<ref id="bibr10-1352458512451943">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Okuda</surname><given-names>DT</given-names></name>
<name><surname>Mowry</surname><given-names>EM</given-names></name>
<name><surname>Cree</surname><given-names>BAC</given-names></name>
<etal/>
</person-group>. <article-title>Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>686</fpage>–<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512451943">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maia</surname><given-names>ACM</given-names><suffix>Jr</suffix></name>
<name><surname>da Rocha</surname><given-names>AJ</given-names></name>
<name><surname>Barros</surname><given-names>BR</given-names></name>
<etal/>
</person-group>. <article-title>Incidental demyelinating inflammatory lesions in asymptomatic patients: A Brazilian cohort with radiologically isolated syndrome and a critical review of current literature</article-title>. <source>Arq Neuropsiquiatr</source> <year>2012</year>; <volume>70</volume>: <fpage>5</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512451943">
<label>12.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Lebrun</surname><given-names>C</given-names></name>
<name><surname>le Page</surname><given-names>E</given-names></name>
<name><surname>Kantarci</surname><given-names>O</given-names></name>
<etal/>
</person-group>. <article-title>Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort</article-title>. <source>Mult Scler J</source>. <comment>Epub ahead of print 2 February 2012</comment> (<access-date>accessed 2 March 2012</access-date>). <comment><ext-link ext-link-type="uri" xlink:href="http://msj.sagepub.com/content/early/2012/02/01/1352458511435931.abstract">http://msj.sagepub.com/content/early/2012/02/01/1352458511435931.abstract</ext-link></comment> DOI: 10.1177/1352458511435931<pub-id pub-id-type="doi">10.1177/1352458511435931</pub-id></citation>
</ref>
<ref id="bibr13-1352458512451943">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Banwell</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>292</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512451943">
<label>14.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>HK.</given-names></name>
</person-group> <source>PACS and imaging informatics: Basic principles and applications</source>. <publisher-loc>Hoboken, NJ</publisher-loc>: <publisher-name>Wiley-Blackwell</publisher-name>, <year>2010</year>.</citation>
</ref>
<ref id="bibr15-1352458512451943">
<label>15.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Weiner</surname><given-names>HL</given-names></name>
<name><surname>Stankiewicz</surname><given-names>JM.</given-names></name>
</person-group> <article-title>Multiple sclerosis: Diagnosis and therapy</article-title>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley and Sons</publisher-name>, <year>2012</year>.</citation>
</ref>
<ref id="bibr16-1352458512451943">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Georgi</surname><given-names>W.</given-names></name>
</person-group> <article-title>Multiple sclerosis. Anatomopathological findings of multiple sclerosis in diseases not clinically diagnosed</article-title>. <source>Schweiz Med Wochenschr</source> <year>1961</year>; <volume>91</volume>: <fpage>605</fpage>–<lpage>607</lpage>. (<comment>German</comment>)</citation>
</ref>
<ref id="bibr17-1352458512451943">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gilbert</surname><given-names>JJ</given-names></name>
<name><surname>Sadler</surname><given-names>M.</given-names></name>
</person-group> <article-title>Unsuspected multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>1983</year>; <volume>40</volume>: <fpage>533</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512451943">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Engell</surname><given-names>T.</given-names></name>
</person-group> <article-title>A clinical patho-anatomical study of clinically silent multiple sclerosis</article-title>. <source>Acta Neurol Scand</source> <year>1989</year>; <volume>79</volume>: <fpage>428</fpage>–<lpage>430</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512451943">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johannsen</surname><given-names>LG</given-names></name>
<name><surname>Stenager</surname><given-names>E</given-names></name>
<name><surname>Jensen</surname><given-names>K.</given-names></name>
</person-group> <article-title>Clinically unexpected multiple sclerosis in patients with mental disorders. A series of 7301 psychiatric autopsies</article-title>. <source>Acta Neurol Belg</source> <year>1996</year>; <volume>96</volume>: <fpage>62</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512451943">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alonso</surname><given-names>A</given-names></name>
<name><surname>Hernan</surname><given-names>MA.</given-names></name>
</person-group> <article-title>Temporal trends in the incidence of multiple sclerosis: A systematic review</article-title>. <source>Neurology</source> <year>2008</year>; <volume>71</volume>: <fpage>129</fpage>–<lpage>135</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512451943">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lyoo</surname><given-names>IK</given-names></name>
<name><surname>Seol</surname><given-names>HY</given-names></name>
<name><surname>Byun</surname><given-names>HS</given-names></name>
<etal/>
</person-group>. <article-title>Unsuspected multiple sclerosis in patients with psychiatric disorders: A magnetic resonance imaging study</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> <year>1996</year>; <volume>8</volume>: <fpage>54</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512451943">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weber</surname><given-names>F</given-names></name>
<name><surname>Knopf</surname><given-names>H.</given-names></name>
</person-group> <article-title>Incidental findings in magnetic resonance imaging of the brains of healthy young men</article-title>. <source>J Neurol Sci</source> <year>2006</year>; <volume>240</volume>: <fpage>81</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512451943">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wasay</surname><given-names>M</given-names></name>
<name><surname>Rizvi</surname><given-names>F</given-names></name>
<name><surname>Azeemuddin</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Incidental MRI lesions suggestive of multiple sclerosis in asymptomatic patients in Karachi, Pakistan</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2011</year>; <volume>82</volume>: <fpage>83</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512451943">
<label>24.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Dua</surname><given-names>T.</given-names></name>
</person-group> <source>Atlas: Multiple sclerosis resources in the world, 2008</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>World Health Organization; Multiple Sclerosis International Federation</publisher-name>, <year>2008</year>.</citation>
</ref>
<ref id="bibr25-1352458512451943">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>D’Amico</surname><given-names>D</given-names></name>
<name><surname>La Mantia</surname><given-names>L</given-names></name>
<name><surname>Rigamonti</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Prevalence of primary headaches in people with multiple sclerosis</article-title>. <source>Cephalalgia</source> <year>2004</year>; <volume>24</volume>: <fpage>980</fpage>–<lpage>984</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512451943">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McDonnell</surname><given-names>GV</given-names></name>
<name><surname>Cabrera-Gomez</surname><given-names>J</given-names></name>
<name><surname>Calne</surname><given-names>DB</given-names></name>
<etal/>
</person-group>. <article-title>Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: The subclinical stage of primary progressive multiple sclerosis may last 10 years</article-title>. <source>Mult Scler</source> <year>2003</year>; <volume>9</volume>: <fpage>204</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512451943">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Seze</surname><given-names>J</given-names></name>
<name><surname>Vermersch</surname><given-names>P</given-names></name>
</person-group>. <article-title>Sequential magnetic resonance imaging follow-up of multiple sclerosis before the clinical phase</article-title>. <source>Mult Scler</source> <year>2005</year>; <volume>11</volume>: <fpage>395</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512451943">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hakiki</surname><given-names>B</given-names></name>
<name><surname>Goretti</surname><given-names>B</given-names></name>
<name><surname>Portaccio</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>‘Subclinical MS’: Follow-up of four cases</article-title>. <source>Eur J Neurol</source> <year>2008</year>; <volume>15</volume>: <fpage>858</fpage>–<lpage>861</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512451943">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mäurer</surname><given-names>M.</given-names></name>
</person-group> <article-title>Radiologisch isoliertes syndrom – Differenzialdiagnose und vorgehen</article-title>. <source>Aktuel Neurol</source> <year>2009</year>; <volume>36</volume>: <fpage>265</fpage>–<lpage>267</lpage>. (<comment>German</comment>)</citation>
</ref>
<ref id="bibr30-1352458512451943">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meuth</surname><given-names>S</given-names></name>
<name><surname>Bittner</surname><given-names>S</given-names></name>
<name><surname>Kleinschnitz</surname><given-names>C.</given-names></name>
</person-group> <article-title>Preclinical multiple sclerosis and therapeutical options</article-title>. <source>Aktuel Neurol</source> <year>2009</year>; <volume>36</volume>(<supplement>Suppl. 3</supplement>): <fpage>S268</fpage>–<lpage>S270</lpage>. (<comment>German</comment>)</citation>
</ref>
<ref id="bibr31-1352458512451943">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bau</surname><given-names>L</given-names></name>
<name><surname>Matas</surname><given-names>E</given-names></name>
<name><surname>Romero-Pinel</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Subclinical demyelinating lesions: Clinical and magnetic resonance imaging follow-up of 13 patients</article-title>. <source>J Neurol</source> <year>2009</year>; <volume>256</volume>: <fpage>S121</fpage>.</citation>
</ref>
<ref id="bibr32-1352458512451943">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spain</surname><given-names>R</given-names></name>
<name><surname>Bourdette</surname><given-names>D.</given-names></name>
</person-group> <article-title>The radiologically isolated syndrome: Look (again) before you treat</article-title>. <source>Curr Neurol Neurosci Rep</source> <year>2011</year>; <volume>11</volume>: <fpage>498</fpage>–<lpage>506</lpage>.</citation>
</ref>
<ref id="bibr33-1352458512451943">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Stefano</surname><given-names>N</given-names></name>
<name><surname>Stromillo</surname><given-names>ML</given-names></name>
<name><surname>Rossi</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis</article-title>. <source>PLoS ONE</source> <year>2011</year>; <volume>6</volume>: <fpage>e19452</fpage>.</citation>
</ref>
<ref id="bibr34-1352458512451943">
<label>34.</label>
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Langdon</surname><given-names>D</given-names></name>
<name><surname>Amato</surname><given-names>M</given-names></name>
<name><surname>Boringa</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)</article-title>. <source>Mult Scler</source>. <comment>Epub ahead of print 21 December 2011</comment> (<access-date>accessed 2 March 2012</access-date>), <comment><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22190573">http://www.ncbi.nlm.nih.gov/pubmed/22190573</ext-link></comment> DOI: 10.1177/1352458511431076<pub-id pub-id-type="doi">10.1177/1352458511431076</pub-id></citation>
</ref>
<ref id="bibr35-1352458512451943">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lebrun</surname><given-names>C</given-names></name>
<name><surname>Blanc</surname><given-names>F</given-names></name>
<name><surname>Brassat</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Cognitive function in radiologically isolated syndrome</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>919</fpage>–<lpage>925</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512451943">
<label>36.</label>
<citation citation-type="gov">
<person-group person-group-type="author">
<name><surname>Amato</surname><given-names>MP</given-names></name>
<name><surname>Hakiki</surname><given-names>B</given-names></name>
<name><surname>Goretti</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Association of MRI metrics and cognitive impairment in radiologically isolated syndromes</article-title>. <source>Neurology</source>. <comment>Epub ahead of print 18 January 2012</comment> (<access-date>accessed 2 Mar 2012</access-date>), <comment><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/22262744">http://www.ncbi.nlm.nih.gov/pubmed/22262744</ext-link></comment> DOI: 10.1212/WNL.0b013e31824528c9<pub-id pub-id-type="doi">10.1212/WNL.0b013e31824528c9</pub-id></citation>
</ref>
<ref id="bibr37-1352458512451943">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eraksoy</surname><given-names>M</given-names></name>
<name><surname>Kurtuncu</surname><given-names>M</given-names></name>
<name><surname>Akman-Demir</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Clinically unsuspected multiple sclerosis: Report of 22 cases and review of the literature</article-title>. <source>Mult Scler</source> <year>2007</year>; <volume>13</volume>(<supplement>Suppl. 2</supplement>): <fpage>S105</fpage>.</citation>
</ref>
<ref id="bibr38-1352458512451943">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sempere</surname><given-names>AP</given-names></name>
<name><surname>López-Celada</surname><given-names>S</given-names></name>
<name><surname>Berenguer-Ruiz</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Radiologically isolated syndrome</article-title>. <source>Rev Neurol</source> <year>2009</year>; <volume>49</volume>: <fpage>599</fpage>–<lpage>600</lpage>. (<comment>Spanish</comment>)</citation>
</ref>
<ref id="bibr39-1352458512451943">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giorgio</surname><given-names>A</given-names></name>
<name><surname>Stromillo</surname><given-names>ML</given-names></name>
<name><surname>Rossi</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Cortical lesions in radiologically isolated syndrome</article-title>. <source>Neurology</source> <year>2011</year>; <volume>77</volume>: <fpage>1896</fpage>–<lpage>1899</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512451943">
<label>40.</label>
<citation citation-type="web">
<source>Medscape Great Debate: Radiologically isolated syndrome</source>, <comment><ext-link ext-link-type="uri" xlink:href="http://www.medscape.com/viewarticle/720673">http://www.medscape.com/viewarticle/720673</ext-link></comment> (<access-date>accessed 4 March 2012</access-date>).<comment>Published: 04/27/2010</comment></citation>
</ref>
<ref id="bibr41-1352458512451943">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chataway</surname><given-names>J.</given-names></name>
</person-group> <article-title>When confronted by a patient with the radiologically isolated syndrome</article-title>. <source>Pract Neurol</source> <year>2010</year>; <volume>10</volume>: <fpage>271</fpage>–<lpage>277</lpage>.</citation>
</ref>
<ref id="bibr42-1352458512451943">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sellner</surname><given-names>J</given-names></name>
<name><surname>Schirmer</surname><given-names>L</given-names></name>
<name><surname>Hemmer</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>The radiologically isolated syndrome: Take action when the unexpected is uncovered?</article-title> <source>J Neurol</source> <year>2010</year>; <volume>257</volume>: <fpage>1602</fpage>–<lpage>1611</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512451943">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>DH</given-names></name>
<name><surname>Weinshenker</surname><given-names>BG</given-names></name>
<name><surname>Filippi</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Differential diagnosis of suspected multiple sclerosis: A consensus approach</article-title>. <source>Mult Scler</source> <year>2008</year>; <volume>14</volume>: <fpage>1157</fpage>–<lpage>1174</lpage>.</citation>
</ref>
<ref id="bibr44-1352458512451943">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goodin</surname><given-names>DS</given-names></name>
<name><surname>Bates</surname><given-names>D.</given-names></name>
</person-group> <article-title>Treatment of early multiple sclerosis: The value of treatment initiation after a first clinical episode</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>1175</fpage>–<lpage>1182</lpage>.</citation>
</ref>
<ref id="bibr45-1352458512451943">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bourdette</surname><given-names>D</given-names></name>
<name><surname>Simon</surname><given-names>J.</given-names></name>
</person-group> <article-title>The radiologically isolated syndrome: Is it very early multiple sclerosis?</article-title> <source>Neurology</source> <year>2009</year>; <volume>72</volume>: <fpage>780</fpage>–<lpage>781</lpage>.</citation>
</ref>
<ref id="bibr46-1352458512451943">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bourdette</surname><given-names>D</given-names></name>
<name><surname>Yadav</surname><given-names>V.</given-names></name>
</person-group> <article-title>The radiologically isolated syndrome revisited: When is it presymptomatic multiple sclerosis?</article-title> <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>680</fpage>–<lpage>681</lpage>.</citation>
</ref>
<ref id="bibr47-1352458512451943">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montalban</surname><given-names>X</given-names></name>
<name><surname>Tintoré</surname><given-names>M</given-names></name>
<name><surname>Swanton</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>MRI criteria for MS in patients with clinically isolated syndromes</article-title>. <source>Neurology</source> <year>2010</year>; <volume>74</volume>: <fpage>427</fpage>–<lpage>434</lpage>.</citation>
</ref></ref-list>
</back>
</article>